Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
18 juil. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 18, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira's LNP Technology Enables Alnylam's Positive Phase II ALN-TTR02 Data
01 juil. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Announces Election of Directors
17 mai 2013 18h15 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Presents LNP Technology Innovations at Scientific Symposium
15 mai 2013 16h15 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 15, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Corporate Update and Announces First Quarter 2013 Results
14 mai 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 14, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results
09 mai 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program
08 mai 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 8, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)
10 avr. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting
09 avr. 2013 15h00 HE
|
Arbutus Biopharma Corporation
TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective Range
Tekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid (Neuroendocrine)...
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results
27 mars 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...